|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS
|
|
|
|
|
|
| Insights from the STAMPEDE Trial Platform |
Marina Parry, BSc, Ph.D. and Gerhardt Attard, MD, Ph.D., FRCP
Marina Parry and Gerhardt Attard join Alicia Morgans in discussing two key studies from the STAMPEDE trial platform, including “Comparison of abiraterone acetate and prednisolone or combination enzalutamide + abiraterone acetate and prednisolone for mHSPC starting ADT: OS results of 2 randomized Phase III trials from the STAMPEDE protocol” and “Clinical qualification of transcriptome signatures for advanced prostate cancer starting ADT with or without abiraterone acetate and prednisolone: an ancillary study of the STAMPEDE AAP trial” .
|
|
|
|
|
|
|
|
|
|
|
| An Ancillary Study of the STAMPEDE Trial Assessing the Clinical Qualification of Transcriptome Signatures for Advanced Prostate Cancer Starting ADT +/- Abiraterone Acetate and Prednisolone |
Gerhardt Attard, MD, Ph.D., FRCP
Gerhardt Attard joins Ashley Ross in discussing an ancillary study of the STAMPEDE trial assessing the clinical qualification of transcriptome signatures for advanced prostate cancer starting ADT with or without abiraterone acetate and prednisolone. |
|
|
|
|
|
|
|
|
|
|
| The Molecular Biology of Prostate Cancer |
Christopher Barbieri, MD, Ph.D. and Matthew Cooperberg, MD, FACS
Christopher Barbieri joins Matthew Cooperberg for a discussion about the molecular biology of localized prostate cancer. Dr. Barbieri explains how the underlying molecular and genomic features that separate prostate cancer subtypes can be studied using DNA sequencing and RNA sequencing. The conversation covers predictive markers including DECIPHER, PAM50, genomic mutations, and oncogenic drivers. |
|
|
|
|
|
|
|
|
|
|
|
Treatment of Unfavorable Intermediate-Risk Prostate Cancer
|
Jason Hafron, MD, Katie S. Murray, DO, MS, FACS
Jason Hafron and Katie Murray join Ashley Ross in a conversation on the treatment of unfavorable intermediate-risk prostate cancer and the value of the genomic classifier useful in guiding treatment considerations.
|
|
|
|
|
|
|
|
|
|
|
| Additional Insights from the STAMPEDE Trial Platform |
| Elena Castro, MD |
| Elena Castro discusses two key studies from the STAMPEDE trial platform, including “Comparison of abiraterone acetate and prednisolone or combination enzalutamide + abiraterone acetate and prednisolone for mHSPC starting ADT: OS results of 2 randomized Phase III trials from the STAMPEDE protocol” presented by Gerhardt Attard, and “Clinical qualification of transcriptome signatures for advanced prostate cancer starting ADT with or without abiraterone acetate and prednisolone: an ancillary study of the STAMPEDE AAP trial” presented by Marina Parry. |
|
|
|
|
|
|
|
|
|
|
| Clinical Qualification of Transcriptome Signatures for Advanced Prostate Cancer Starting ADT with or Without Abiraterone Acetate and Prednisolone: An Ancillary Study of the STAMPEDE AAP Trial |
| Marina Parry, BSc, Ph.D. |
| Marina Parry discusses an ancillary study of the STAMPEDE trial assessing clinical qualification of transcriptome signatures for advanced prostate cancer starting ADT with or without abiraterone acetate and prednisolone. Exploratory analysis reveals different signatures are prognostic in M1 and M0, with an interaction with metastatic stage observed in immune related signatures. |
|
|
|
|
|
| Comparison of Abiraterone Acetate and Prednisolone or Combination Enzalutamide + Abiraterone Acetate and Prednisolone for mHSPC Starting ADT: OS Results of 2 Randomized Phase III Trials from the STAMPEDE Protocol
|
| Gerhardt Attard, MD, Ph.D.
|
| Gerhardt Attard discusses a comparison of abiraterone acetate and prednisolone or combination enzalutamide + abiraterone acetate and prednisolone for mHSPC starting ADT. Enzalutamide + abiraterone acetate and prednisolone need not be combined for mHSPC (nor for high-risk localized prostate cancer). Clinically important improvements in OS when adding abiraterone acetate and prednisolone to ADT are maintained at 7 years.
|
|
|
|
|
|
| How Can Treatment Be Individualized By Using Genomic Classifiers? |
| Felix Feng, MD |
| Felix Feng discusses how treatment can be individualized by using genomic classifiers. Dr. Feng highlights that genomic biomarkers are included in certain treatment guidelines for the management of PSA recurrences. In the NCCN guidelines, the Decipher molecular assay is recommended for risk stratification among men with PSA persistence or recurrence. |
|
|
|
|
|
|
